Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study evaluates the performance of the CorPath 200 System to deliver guide wires and balloons to blockages in the arteries of the leg.
The CorPath 200 System is currently marketed for remotely delivering guide wires, balloons and stents to blockages in the coronary arteries. This study will evaluate the feasibility of CorPath 200 System to deliver guide wires and balloons to blockages in non-coronary arteries.
Guide wires and balloons are delivered to blockages in the lower limbs manually by doctors.If this study shows that guide wires and balloons can be safely delivered to blockages in the lower limbs, then it will be an alternative for physicians.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CorPath 200 System | Experimental | CorPath 200 System for remote delivery and manipulation of guidewires and balloon catheters during percutaneous vascular intervention. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CorPath 200 System | Device | Remote delivery of guide wires and balloon catheters for use in percutaneous vascular interventions (PVI). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Device Technical Success | Number of lesions for which there was technical success" as accurate and appropriate. | Procedure |
| Adverse Events | No device-related serious adverse events during the procedure. | Procedure |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical Procedural Success | Defined as <50% residual stenosis in all CorPath 200 System treated lesions at the completion of the interventional procedure (without an unplanned switch to the manual procedure) in the absence of device-related SAE, either within twenty-four (24) hours of the procedure or prior to hospital discharge, whichever occurs first. | 24-hours |
Not provided
Inclusion Criteria:
General Inclusion
Angiographic Inclusion
Presence of superficial femoral artery and/or iliac stenosis (>50%) or occlusion of up to 50 mm in length as determined by angiogram prior to index interventional procedure.
Exclusion Criteria:
General Exclusion
Angiographic Exclusion
Target vessel:
Lesion is highly calcified;
Lesion requires use of any atherectomy device during the procedure;
Has a pre-existing target artery aneurysm or perforation or dissection of the target artery prior to initiation of the interventional procedure.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Marianne Brodmann, M.D. | Medizinische Universität Graz | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medizinische Univeristät Graz | Graz | A-8036 | Austria |
Not provided
During February - April 2015 period 20 participants were enrolled in the RAPID study at one (1) clinical site.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | CorPath 200 System | CorPath 200 System for remote delivery and manipulation of guidewires and balloon catheters during percutaneous vascular intervention. CorPath 200 System: Remote delivery of guide wires and balloon catheters for use in percutaneous vascular interventions (PVI). |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Baseline Demographics | Baseline measures for the treated subjects. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Device Technical Success | Number of lesions for which there was technical success" as accurate and appropriate. | 29 lesions treated in 20 subjects. | Posted | Number | lesions | Procedure | lesions | lesions |
|
|
All subjects will be followed post-CorPath procedure through 24 hours or hospital discharge, whichever occurs first.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Device-related Periprocedural Event | The primary safety measure was the absence of device-related serious adverse events during the procedure. These were defined as adverse events related to the use of the robotic device that resulted in hospitalization, prolonged hospitalization, were life threatening, or resulted in death. |
Not provided
Not provided
This study represents a single high-volume tertiary care center experience and the results need to be replicated by multiple users to show the general applicability of these findings.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Vice President, Clinical and Regulatory Affairs | Corindus Vascular Robotics | 260-615-8892 | john.vanvleet@corindus.com |
Not provided
| ID | Term |
|---|---|
| D058729 | Peripheral Arterial Disease |
| D000089802 | Chronic Limb-Threatening Ischemia |
| D007383 | Intermittent Claudication |
| ID | Term |
|---|---|
| D050197 | Atherosclerosis |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Fluoroscopy Time | As recorded by an X-ray system utilized during the procedure. | Procedure |
| Contrast Volume | Total amount of contrast used during CorPath procedure. | Procedure |
| Total Procedure Time | Defined as the time measured from the insertion of the hemostasis sheath until procedure complete (guide catheter removed). | Procedure |
| Interventional Procedure Time | Defined as the time measured from the insertion of the guide catheter until the removal of the guide catheter. | Procedure |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
|
| lesions |
|
|
| Primary | Adverse Events | No device-related serious adverse events during the procedure. | Device-related events that occured in subjects treated. | Posted | Count of Participants | Participants | Procedure |
|
|
|
| Secondary | Clinical Procedural Success | Defined as <50% residual stenosis in all CorPath 200 System treated lesions at the completion of the interventional procedure (without an unplanned switch to the manual procedure) in the absence of device-related SAE, either within twenty-four (24) hours of the procedure or prior to hospital discharge, whichever occurs first. | Achievement of <50% residual stenosis in all robotic system treated lesions at the completion of the interventional procedure without an unplanned switch to the manual procedure in the absence of device-related serious adverse events. | Posted | Number | participants | 24-hours |
|
|
|
| Secondary | Fluoroscopy Time | As recorded by an X-ray system utilized during the procedure. | Procedure time for subjects measured from the insertion of the hemostasis sheath until the removal of the guide catheter. | Posted | Mean | Standard Error | min | Procedure |
|
|
|
| Secondary | Contrast Volume | Total amount of contrast used during CorPath procedure. | Total amount of contrast used during CorPath procedure for subjects. | Posted | Mean | Standard Error | ml | Procedure |
|
|
|
| Secondary | Total Procedure Time | Defined as the time measured from the insertion of the hemostasis sheath until procedure complete (guide catheter removed). | Total procedure time for subjects. | Posted | Mean | Standard Deviation | min | Procedure |
|
|
|
| Secondary | Interventional Procedure Time | Defined as the time measured from the insertion of the guide catheter until the removal of the guide catheter. | Interventional procedure time for subjects. | Posted | Mean | Standard Deviation | min | Procedure |
|
|
|
| 0 |
| 20 |
| 0 |
| 20 |
| 0 |
| 20 |
Not provided
Not provided
| D002318 |
| Cardiovascular Diseases |
| D016491 | Peripheral Vascular Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D007511 | Ischemia |
| D012816 | Signs and Symptoms |